Changes in Emotions Related to Medication Used to Treat ADHD. Part II: Clinical Approaches

Autor/inn/en	Findling, Robert L.; Brams, Matthew; Childress, Ann C.; Lopez, Frank A.; Manos, Michael J.; Jensen, Peter S.
Titel	Changes in Emotions Related to Medication Used to Treat ADHD. Part II: Clinical Approaches
Quelle	In: Journal of Attention Disorders, 15 (2011) 2, S.113-121 (9 Seiten) PDF als Volltext Verfügbarkeit
Sprache	englisch
Dokumenttyp	gedruckt; online; Zeitschriftenaufsatz
ISSN	1087-0547
DOI	10.1177/1087054710381232
Schlagwörter	Attention Deficit Hyperactivity Disorder; Research Methodology; Drug Therapy; Emotional Response; Neurological Impairments; Behavior Problems; Child Behavior; Symptoms (Individual Disorders); Comparative Analysis; Literature Reviews; Rating Scales; Clinical Diagnosis; Case Studies; Behavior Modification + Suchen Sie Ihr Suchwort? Research method; Forschungsmethode; Emotionales Verhalten; Neurodegenerative Erkrankung; Psychiatrische Symptomatik; Rating-Skala; Case study; Fallstudie; Case Study; Behaviour modification; Verhaltensänderung
Abstract	ADHD is one of the most common neurobehavioral disorders of childhood, and FDA-approved medications offer an efficacious treatment option. However, case reports and anecdotal sources suggest that children can have emotional responses, both salutary and detrimental, to these agents. We have previously conducted a comprehensive literature review and found very few research studies systematically examining changes in emotional expression (EE) associated with ADHD medication use. In addition, no empirical data pertaining to the management of these responses could be found. Although few methodologically stringent data are available for changes in EE, such changes should be recognized and measured to determine appropriate responses by clinicians and to maximize treatment benefits and reduce side effects. In this companion report, we draw on available research evidence and clinical experience to explore typical clinical manifestations, differential diagnosis, scales for monitoring, and management approaches of EE observed with pharmacologic treatment of ADHD. In the future, controlled clinical trials of ADHD pharmacotherapy should employ standardized ratings of EE at baseline, during and after treatment. In addition, future research studies should examine various management approaches of these EE changes, to ensure maximal treatment benefits and minimal risks to patients with ADHD who are treated with medication. (Contains 2 tables and 1 figure.) [For Part I, see EJ913767.] (As Provided).
Anmerkungen	SAGE Publications. 2455 Teller Road, Thousand Oaks, CA 91320. Tel: 800-818-7243; Tel: 805-499-9774; Fax: 800-583-2665; e-mail: journals@sagepub.com; Web site: http://sagepub.com
Erfasst von	ERIC (Education Resources Information Center), Washington, DC
Update	2017/4/10